Meeting
2023 ASCO Annual Meeting
A 19-protein signature to predict outcomes in a cohort of stage II and III CRC.
Authors
Rosemary Habib
The Westmead Institute for Medical Research, Faculty of Medicine, The University of Sydney, Westmead, NSW, Australia
Rosemary Habib , Adel Aref , Asim Anees , Mohashin Pathan , Duncan McLeod , Rosemary L Balleine , Daniel Bucio-Noble , Zainab Noor , Li Ma , Lucy Wang , Judith Heads , Naheela Lalee , Clare Loudon , Jennifer Koh , Peter Hains , Phillip J Robinson , Qing Zhong , Kenneth Micklethwaite , Adnan Nagrial , Roger R Reddel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3129)
DOI
10.1200/JCO.2023.41.16_suppl.3129
Abstract #
3129
Poster Bd #
327
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant chemoradiation does not improve outcomes for patients undergoing resection for upper rectal cancer: A US Rectal Cancer Consortium analysis.
First Author: Caroline Medin
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical significance of Bacteroides fragilis as potential prognostic factor in colorectal cancer patients.
First Author: Yuriko Matsumiya
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Impact of previous adjuvant oxaliplatin combination therapy on survival in elderly colorectal cancer patients with recurrence.
First Author: Yusuke Nagata